OKYO Pharma Limited
NASDAQ:OKYOBiotechnology
+$0.01 today
- Market cap
- $57.73M
- Beta
- 0.02
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.12
Volume 0.24M
Average 0.07M
OKYO Net Income
Bottom-line profit, the starting point for calculating cash from operations.
OKYO Pharma LimitedNASDAQ: OKYO
Net Income · Q2 FY2026 · quarter ended Sep 2025
Net income grows 96497.0% year over year
Q2 FY2026 net income of $2.59M (cash outflow) rose 96497.0% year over year. Over 3 fiscal years it compounded at +8.6% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate of -$3.95M (-50.5%) for the fiscal year ending Mar 2026, a step up from the -52.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2025
- -$2.59M— QoQ
- Last fiscal yearMar 2025
- -$7.97M-52.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +96497.0% | — | — |
| 1 year | -52.6% | -50.5% | +2.2 pp |
| 3-year CAGR | +8.6% | +43.0% | +34.4 pp |
| 5-year CAGR | +6.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (7.97M) USD
- Year-over-year change
- +52.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-03-31 | (7.97M) | +52.6% |
| FY2024 | 2024-03-31 | (16.83M) | -26.7% |
| FY2023 | 2023-03-31 | (13.28M) | -113.7% |
| FY2022 | 2022-03-31 | (6.22M) | -84.0% |
| FY2021 | 2021-03-31 | (3.38M) | — |
Net Income vs competitors
How OKYO compares with its peers on the latest reported figures
- OKYO's FY2025 net income of $7.97M is the smallest of the 10 companies compared; the peer median is $33.51M.
- Its year-over-year change of -52.6% is the 8th highest of 9, against a peer median of +19.3%.
- Over three fiscal years its annual growth of +8.6% compares with a peer median of -4.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $124.13M | -44.6% | -16.7% | — | |
| LTM Mar 2026 | $113.22M | -48.4% | +6.6% | — | |
| LTM Mar 2026 | $70.36M | +26.1% | -14.6% | 44.8% | |
| LTM Mar 2026 | $34.98M | +67.3% | +52.9% | — | |
| LTM Mar 2026 | $33.51M | +15.3% | -4.4% | 25009.7% | |
| LTM Mar 2026 | $21.13M | +23.3% | +20.1% | 266.1% | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $20.6M | -67.7% | -30.2% | 288.3% |
| FY2025 | $18.43M | +94.4% | +13.7% | — | |
| LTM Jun 2024 | $14.92M | — | -25.7% | 227.4% | |
| FY2025 | $7.97M | -52.6% | +8.6% | — | |
| Peer median (excluding OKYO) | $33.51M | +19.3% | -4.4% | 266.1% | |
Competitors are the stored peer set for OKYO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Mar 2021 | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 |
|---|---|---|---|---|---|
| Net Income | (3.38M) | (6.22M) | (13.28M) | (16.83M) | (7.97M) |
| Depreciation & Amortization | 13.11K | 2.33K | 3.8K | 3.87K | 2.56K |
| Deferred Income Tax | 92.95K | (9.41K) | 250.35K | 0 | 0 |
| Stock-Based Compensation | 544.39K | 1.72M | 1.27M | 1.12M | 734.99K |
| Change in Working Capital | 1.04M | (1.02M) | 4.14M | 2.67M | 3.63M |
| Accounts Receivables | 205.07K | 27.38K | 167.72K | 440.26K | (90.4K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | (297.99K) | 0 | 2.8M | 0 |
| Other Working Capital | 839.78K | (753.25K) | 3.98M | (570.08K) | 3.72M |
| Other Non-Cash Items | 83.01K | 61.72K | (84.16K) | 3.54M | 1.8M |
| Operating Cash Flow | (1.6M) | (5.47M) | (7.7M) | (9.49M) | (1.81M) |
| Capital Expenditures | (6.94K) | (1.67K) | (5.92K) | (3) | (1.21K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (11.15K) | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (21) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (18.11K) | (1.67K) | (5.92K) | 0 | (1.21K) |
| Debt Repayment | 7.58M | 0 | 2M | 0 | 950K |
| Common Stock Issued | 230.02K | 1.43M | 7.32M | 6.21M | 1.71M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 15.87K | 725.51K | 9.32M | 0 | 1.71M |
| Financing Cash Flow | 7.83M | 2.15M | 9.32M | 6.21M | 2.66M |
| Effect of Forex Changes | 445.22K | (872.14K) | (277.54K) | 63.5K | (109.55K) |
| Net Change in Cash | 6.65M | (4.19M) | 1.34M | (3.22M) | 734.05K |
| Free Cash Flow | (1.61M) | (5.47M) | (7.7M) | (9.49M) | (1.81M) |
OKYO Pharma Limited
NASDAQ:OKYO
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.